应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09688 再鼎医药
休市中 10-23 16:08:09
17.780
-0.060
-0.34%
最高
17.960
最低
16.710
成交量
664.28万
今开
17.560
昨收
17.840
日振幅
7.01%
总市值
202.34亿
流通市值
202.34亿
总股本
11.38亿
成交额
1.16亿
换手率
0.58%
流通股本
11.38亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
美股异动 | 再鼎医药(ZLAB.US)涨逾2% 在研ADC ZociⅠb期数据积极
智通财经 · 10-23 23:40
美股异动 | 再鼎医药(ZLAB.US)涨逾2% 在研ADC ZociⅠb期数据积极
再鼎医药（09688）宣布11月5日公布2026年第三季度业绩并举行电话会议
公告速递 · 10-23 21:31
再鼎医药（09688）宣布11月5日公布2026年第三季度业绩并举行电话会议
再鼎医药Zoci一线小细胞肺癌数据支持推进全球三期研究 探索以ADC替代含铂化疗
证券日报 · 10-23 20:07
再鼎医药Zoci一线小细胞肺癌数据支持推进全球三期研究 探索以ADC替代含铂化疗
再鼎医药(09688.HK)：Zocilurtatug Pelitecan(Zoci，前称ZL-1310)在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征
中金财经 · 10-23 19:50
再鼎医药(09688.HK)：Zocilurtatug Pelitecan(Zoci，前称ZL-1310)在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征
再鼎医药(09688.HK)：zocilurtatug pelitecan在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征
智通财经 · 10-23 19:02
再鼎医药(09688.HK)：zocilurtatug pelitecan在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征
港股异动丨再鼎医药一度跌超6%，配股筹逾19亿港元
中金财经 · 10-23 13:17
港股异动丨再鼎医药一度跌超6%，配股筹逾19亿港元
再鼎医药：私人配售美国存托股份净筹2.41亿美元 用于DLL3 ADC药物开发
财中社 · 10-23 09:25
再鼎医药：私人配售美国存托股份净筹2.41亿美元 用于DLL3 ADC药物开发
再鼎医药(09688.HK)拟私人配售1134万股美国存托股份 净筹约2.41亿美元
智通财经 · 10-23 08:53
再鼎医药(09688.HK)拟私人配售1134万股美国存托股份 净筹约2.41亿美元
再鼎医药（09688）拟发行1134万股美国存托股份 较港股近5日平均收市价约折让6.77%
金吾财讯 · 10-23 08:40
再鼎医药（09688）拟发行1134万股美国存托股份 较港股近5日平均收市价约折让6.77%
再鼎医药（09688）拟22.04美元/股私募发行1,134万股ADS 预计募资约2.50亿美元
公告速递 · 10-23 08:36
再鼎医药（09688）拟22.04美元/股私募发行1,134万股ADS 预计募资约2.50亿美元
港股通创新药急转直下，发生了什么？520880标的指数跌逾4.6%，再鼎医药、康方生物重挫
新浪基金 · 10-22 11:01
港股通创新药急转直下，发生了什么？520880标的指数跌逾4.6%，再鼎医药、康方生物重挫
再鼎医药盘中跌超5%，ESMO临近国产创新药将披露关键数据
同花顺 · 10-22 09:36
再鼎医药盘中跌超5%，ESMO临近国产创新药将披露关键数据
创新药股早盘延续涨势 再鼎医药及云顶新耀均涨超5%
新浪港股 · 10-21 10:52
创新药股早盘延续涨势 再鼎医药及云顶新耀均涨超5%
港股异动 | 创新药股延续涨势 多项重要数据将于ESMO公布 平台型BD接连落地传递信心
智通财经 · 10-21 10:30
港股异动 | 创新药股延续涨势 多项重要数据将于ESMO公布 平台型BD接连落地传递信心
【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振
金吾财讯 · 10-21
【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振
再鼎医药（09688）发布提名及企业管治委员会最新章程
公告速递 · 10-21
再鼎医药（09688）发布提名及企业管治委员会最新章程
异动解读｜再鼎医药盘中上涨5.18%，ZL-1503首个临床数据即将公布
行情直击 · 10-16
异动解读｜再鼎医药盘中上涨5.18%，ZL-1503首个临床数据即将公布
创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%
老虎资讯综合 · 10-16
创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%
生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%
金吾财讯 · 10-16
生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%
【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会
金吾财讯 · 10-16
【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会
暂无数据
公司概况
公司名称：
再鼎医药
所属市场：
SEHK
上市日期：
--
主营业务：
再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":17.78,"timestamp":1792742889009,"preClose":17.84,"halted":0,"volume":6642800,"delay":0,"changeRate":-0.0033632286995514977,"floatShares":1138000000,"shares":1138000000,"eps":-1.2568287155035174,"marketStatus":"休市中","change":-0.06,"latestTime":"10-23 16:08:09","open":17.56,"high":17.96,"low":16.71,"amount":116276178,"amplitude":0.070067,"askPrice":17.78,"askSize":85000,"bidPrice":17.77,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":-1.3319034137695767,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":7,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":17.84,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":1.9169590913011798,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688/tweets","defaultTab":"tweets","newsList":[{"id":"2677976895","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾2% 在研ADC ZociⅠb期数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2677976895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677976895?lang=zh_cn&edition=full","pubTime":"2026-10-23 23:40","pubTimestamp":1792770042,"startTime":"0","endTime":"0","summary":"消息面上，10月23日，再鼎医药公布了旗下在研抗体偶联药物Zocilurtatug Pelitecan用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。安全性方面，在上述33例接受双药治疗的患者中，与Zoci相关的3级及以上不良事件发生率为9.1%。再鼎医药表示，上述研究结果支持进一步探索以ADC联合免疫治疗替代传统含铂化疗的治疗方案。公司计划于2026年底前启动一项全球随机Ⅲ期临床研究，评估Zoci联合免疫治疗用于广泛期小细胞肺癌一线治疗的疗效与安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4548","BK1574","BK1161","09688","BK4531","BK4526","BK4585","LU2488822045.USD","BK4588","BK1588","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184970751","title":"再鼎医药（09688）宣布11月5日公布2026年第三季度业绩并举行电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1184970751","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184970751?lang=zh_cn&edition=full","pubTime":"2026-10-23 21:31","pubTimestamp":1792762294,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司10月23日发布公告称，董事会审计委员会将于2026年11月5日（星期四）审议并批准公司及其附属公司截至2026年9月30日止三个月及九个月的未经审计季度业绩，并于当日对外披露。业绩公布后，管理层计划于2026年11月5日美国东部时间上午8:00／香港时间当日下午9:00举办现场业绩电话会及网络直播，讨论业绩表现并回答提问。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922196","title":"再鼎医药Zoci一线小细胞肺癌数据支持推进全球三期研究 探索以ADC替代含铂化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922196","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922196?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:07","pubTimestamp":1792757220,"startTime":"0","endTime":"0","summary":"10月23日，再鼎医药有限公司（以下简称“再鼎医药”）公布了旗下在研抗体偶联药物（ADC）ZocilurtatugPelitecan（以下简称“Zoci”，原代号ZL-1310）用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。相关结果将于10月26日在2026年欧洲肿瘤内科学会（ESMO）大会上展示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906538190.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906538190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09688","LU2488822045.USD","BK4526","BK4139","BK4585","BK1574","BK4588","ZLAB","BK1588","BK1161","BK4548","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677248139","title":"再鼎医药(09688.HK)：Zocilurtatug Pelitecan(Zoci，前称ZL-1310)在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=2677248139","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677248139?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:50","pubTimestamp":1792756207,"startTime":"0","endTime":"0","summary":"格隆汇10月23日丨再鼎医药公告，中国上海和美国马萨诸塞州剑桥市—2026年10月23日—再鼎医药有限公司，一家以创新为驱动的全球生物制药公司，今日公布了一项评估zocilurtatug pelitecan联合阿替利珠单抗用于广泛期小细胞肺癌一线治疗的全球1b期临床研究的首个数据。\"公司在这一不含化疗的标准方案中所观察到的确认的高缓解率和令人鼓舞的持久性及耐受良好的安全性特征尤为出色。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261023/32406819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4531","BK4526","BK1588","09688","ZLAB","LU2488822045.USD","BK1161","BK4588","BK4139","BK4548","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677195926","title":"再鼎医药(09688.HK)：zocilurtatug pelitecan在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=2677195926","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677195926?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:02","pubTimestamp":1792753348,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","LU2488822045.USD","BK1574","BK1588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677917202","title":"港股异动丨再鼎医药一度跌超6%，配股筹逾19亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677917202","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677917202?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:17","pubTimestamp":1792732642,"startTime":"0","endTime":"0","summary":"港股市场再鼎医药(9688.HK)一度跌超6%，报16.71港元，股价创8月7日以来新低。消息面上，再鼎医药公布，与投资者订立证券购买协议，配售1134万股美国存托股份(ADS)，作价每股22.04美元，相当约17.28港元，较港股昨日收市折让约3.14%，集资约2.5亿美元(约19.49亿港元)。公司指出，拟将所得款项净额主要用于支持其Delta样配体3(DLL3)抗体偶联药物(ADC)靶向Zocilurtatug Pelitecan(zoci)的持续全球开发。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/23/20261023181068.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/23/20261023181068.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261023/32406243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4526","BK4531","KCAI","VXUS","BK1588","09688","BK1161","ZLAB","BK4139","LU2488822045.USD","BK1574","BK4585","BK4588","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916314","title":"再鼎医药：私人配售美国存托股份净筹2.41亿美元 用于DLL3 ADC药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916314","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916314?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:25","pubTimestamp":1792718700,"startTime":"0","endTime":"0","summary":"10月23日，再鼎医药（09688/ZLAB）发布公告，公司于2026年10月22日与投资者签订了证券购买协议，计划通过私人配售向投资者发行和出售合共1134万股美国存托股份，代表合计面值为680.4美元的1.13亿股相关股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233905143872.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233905143872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK4548","BK4139","BK4526","BK1161","BK4585","BK1574","BK1588","BK4588","ZLAB","09688","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677132849","title":"再鼎医药(09688.HK)拟私人配售1134万股美国存托股份 净筹约2.41亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677132849","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677132849?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:53","pubTimestamp":1792716791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09688","BK1161","BK1588","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677509913","title":"再鼎医药（09688）拟发行1134万股美国存托股份 较港股近5日平均收市价约折让6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677509913","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677509913?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:40","pubTimestamp":1792716003,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 发布公告，于2026年10月22日，公司与投资者订立证券购买协议，据此，公司同意按美国存托股份价格向投资者发行及出售合共11,340,000股美国存托股份，约为于本公告日期现有已发行普通股约9.97%；及经配发及发行相关股份扩大后已发行普通股约9.06%。每股美国存托股份代表十股普通股作为相关股份。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NjM1YWNhMGUzZGNhNThhMTg4MzM5MDkyOTUwOA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NjM1YWNhMGUzZGNhNThhMTg4MzM5MDkyOTUwOA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1574","BK1588","BK4531","BK4526","BK4548","BK4585","KCAI","ZLAB","VXUS","LU2488822045.USD","09688","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166343539","title":"再鼎医药（09688）拟22.04美元/股私募发行1,134万股ADS 预计募资约2.50亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166343539","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166343539?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:36","pubTimestamp":1792715774,"startTime":"0","endTime":"0","summary":"10月23日，再鼎医药有限公司（09688，纳斯达克：ZLAB）公告称，公司已于2026年10月22日（美国东部时间）与多家投资者签署证券购买协议，拟通过私人配售方式发行及出售合计11,340,000股美国存托股份（ADS），每股ADS对应10股普通股，合计对应1.13亿股普通股，约占本公告日已发行普通股的9.97%，配售完成后占扩大发行后已发行普通股的9.06%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677873639","title":"港股通创新药急转直下，发生了什么？520880标的指数跌逾4.6%，再鼎医药、康方生物重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2677873639","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677873639?lang=zh_cn&edition=full","pubTime":"2026-10-22 11:01","pubTimestamp":1792638060,"startTime":"0","endTime":"0","summary":"10月22日，港股通创新药修复戛然而止，行情急转直下，港股通创新药ETF华宝标的指数下挫逾4.6%，失守所有均线。最新数据显示，截至最新，港股通创新药ETF华宝标的指数市盈率TTM为33.93倍，已回落至近3年39%分位点，配置性价比凸显。低位吸纳港股通创新药核心资产，关注T+0交易工具——港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，近7成仓位押注创新药研发龙头。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-10-22/doc-iniwaezr5258400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FLHK","159992","BK1574","BK4139","LU0348784397.USD","IE00BPRC5H50.USD","LU2488822045.USD","BK4548","LU2778985437.USD","06978","IBBQ","LU0348783233.USD","LU0348825331.USD","LU0417516738.SGD","LU2476274720.SGD","520880","BK4588","ZLAB","LNGR","LU2476274308.USD","BK1161","LU0540923850.HKD","09688","09926","BK4585","LU0348767384.USD","LU0417516571.SGD","LU0417516902.SGD","LU1720050803.USD","MEDX","IE00B543WZ88.USD","KURE","BK4531","IE00B5MMRT66.SGD","LU0561508036.HKD","BK1588","LU1961090484.USD","LU0348766576.USD","LU1794554557.SGD","LU0348735423.USD","BK4526","LU0348827113.USD","LU2399975544.HKD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677984892","title":"再鼎医药盘中跌超5%，ESMO临近国产创新药将披露关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677984892","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677984892?lang=zh_cn&edition=full","pubTime":"2026-10-22 09:36","pubTimestamp":1792632960,"startTime":"0","endTime":"0","summary":"10月22日，再鼎医药(09688.HK)盘中跌超5%，截至9时34分，跌5.26%，报18.74港元/股，成交额506.01万港元。消息面上，10月21日，前三季度创新药对外技术授权约1300亿美元接近去年全年，2026年 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261022/c680961480.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261022/c680961480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159992","BK4585","BK4139","09688","IBBQ","BK1161","BK4526","BK1574","LNGR","BK4588","BK4531","LU2488822045.USD","BK4548","MEDX","ZLAB","06978","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677460856","title":"创新药股早盘延续涨势 再鼎医药及云顶新耀均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677460856","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677460856?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:52","pubTimestamp":1792551120,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端创新药股早盘延续涨势，截至发稿，再鼎医药（09688）上涨5.67%，报19.93港元；云顶新耀（01952）上涨5.21%，报35.56港元；映恩生物-B（09606）上涨2.61%，报173港元；康方生物（09926）上涨3.23%，报94.35港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-21/doc-inivyaat6202848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ZLAB","BK4526","01952","BK1583","159992","BK4531","LNGR","MEDX","BK4585","BK4548","BK1588","BK4139","BK4588","LU2488822045.USD","BK1161","06978","BK1574","IBBQ","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677646635","title":"港股异动 | 创新药股延续涨势 多项重要数据将于ESMO公布 平台型BD接连落地传递信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2677646635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677646635?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:30","pubTimestamp":1792549810,"startTime":"0","endTime":"0","summary":"国金证券认为，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","LU0348735423.USD","IE00B5MMRT66.SGD","LU0348825331.USD","LU2778985437.USD","VXUS","LU2543165471.USD","LU0348827113.USD","LU1720050803.USD","LU0417516902.SGD","159992","KURE","LU0561508036.HKD","01952","09926","LU0348784397.USD","BK4588","LU0417516738.SGD","IE00B543WZ88.USD","LU2488822045.USD","LU0348767384.USD","MEDX","06978","HK0000252152.HKD","KCAI","09606","IBBQ","HK0000500386.USD","LU2476274308.USD","BK1574","LNGR","LU0348783233.USD","LU0540923850.HKD","BK4585","BK1583","LU0417516571.SGD","BK1161","LU2476274720.SGD","BK1588","LU1794554557.SGD","LU2399975544.HKD","HK0000252160.HKD","LU0348766576.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764599.SGD","LU0348784397.USD","MEDX","BK1141","BK1589","LU0417516571.SGD","01093","06160","LU0516422366.SGD","09926","LU1807302812.USD","LU0588546209.SGD","02616","600109","01877","02269","IE0008368742.USD","LU0455707207.USD","09688","159992","LU0128526141.USD","02142","LU0456846285.SGD","IBBQ","BK0183","LU0348783233.USD","LU0516422440.USD","KURE","LU0540923850.HKD","IE00BPRC5H50.USD","01177","BK1574","LU0823426308.USD","LU2097828714.EUR","LU1770034418.SGD","IE00B031HY20.USD","LU1794554557.SGD","LU1226288170.HKD","09995","LU0228659784.USD","01801","06185","LU0128522744.USD","LNGR","LU1951186391.HKD","LU1303224171.USD","KCE","IE00B0JY6N72.USD","06978","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107128899","title":"再鼎医药（09688）发布提名及企业管治委员会最新章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1107128899","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107128899?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:16","pubTimestamp":1792541765,"startTime":"0","endTime":"0","summary":"2026年10月20日，再鼎医药公告称，公司董事会已正式通过《提名及企业管治委员会章程》。该章程明确了提名及企业管治委员会的宗旨、组成、程序管理以及主要职责，重点内容如下：。委员会的设立旨在履行董事会授予的企业管治及董事提名相关职责。– 委员会成员不少于三名。– 委员会可聘请外部顾问，并由公司提供所需资金。委员会各成员可根据具体情况，对相关事项的重要性及关注程度自行判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186432543","title":"异动解读｜再鼎医药盘中上涨5.18%，ZL-1503首个临床数据即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1186432543","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186432543?lang=zh_cn&edition=full","pubTime":"2026-10-16 11:11","pubTimestamp":1792120263,"startTime":"0","endTime":"0","summary":"10月16日，再鼎医药盘中上涨5.18%，报18.89港元，成交额4441.79万港元。消息面上，公司日前宣布，评估ZL-1503的首个临床研究数据将首次在美国过敏、哮喘与免疫学会年度科学会议上公布，成为股价走强的直接催化。此次将披露的为ZL-1503 1／1b期首次人体试验在健康志愿者中的结果，内容包括单次给药后的药代动力学数据、不同剂量下AD相关生物标志物的药效动力学数据，以及初步安全性与免疫原性数据。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药盘中走强，ZL-1503临床数据将首发","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109072607","title":"创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109072607","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109072607?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:51","pubTimestamp":1792115499,"startTime":"0","endTime":"0","summary":"港股创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%，百济神州涨超6%，再鼎医药涨近5%，药明合联、药明生物涨超4%，药明康德涨近4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","01548","02268","02269","09688","02162","06160","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675542315","title":"生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675542315","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675542315?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:37","pubTimestamp":1792114658,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，康诺亚-B 涨9.00%，金斯瑞生物科技涨7.53%，百济神州涨5.38%，科伦博泰生物涨5.25%，再鼎医药涨4.46%，君实生物涨3.71%，泰格医药涨3.65%，复宏汉霖涨2.99%。中信建投证券表示，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU1770034418.SGD","01548","HK0000320264.USD","LU1303224171.USD","BK1576","BK1161","399441","BK1587","HK0000306685.HKD","LU0228659784.USD","02696","02162","LU2488822045.USD","01877","HK0000306701.USD","BK1141","LU0196878994.USD","LU1719994722.HKD","LU0588546209.SGD","BK1588","BK1515","BK4585","BK1574","03347","06990","161726","HK0000165453.HKD","06160","09688","BK4588","LU0828237510.HKD","KURE","LU0307460666.USD","BK1583","LU1969619763.USD","BK1500","XBI","BK4581","HK0000320223.HKD","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","LU1242518857.USD","LU0417516902.SGD","LU0501845795.SGD","LU1226287792.SGD","LU0128526141.USD","06160","01093","KCE","LU0348767384.USD","BK1610","LU0634319403.HKD","02616","LU0823426480.USD","LU0052750758.USD","09939","09995","LU1226287875.USD","01801","LU0228659784.USD","601066","LU0540923850.HKD","IE00BZ08YR35.GBP","LU1251922891.USD","09926","LU0314109678.HKD","BK1141","LU0181495838.USD","06185","BK1515","09688","BK1583","01177","LU0326950275.SGD","LU1951186391.HKD","LU1969619763.USD","02269","SG9999002562.SGD","BK1500","LU0072913022.USD","KURE","02142","LU0359201612.USD","LU0979878070.USD","LU0819121731.USD","01877","SG9999011746.SGD","LU0348827113.USD","159938","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0441},{"period":"1month","weight":-0.1557},{"period":"3month","weight":0.156},{"period":"6month","weight":0.0097},{"period":"1year","weight":-0.1844},{"period":"ytd","weight":0.3026}],"compareEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.111},{"period":"1year","weight":-0.1107},{"period":"ytd","weight":-0.099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052949},{"month":8,"riseRate":0.666667,"avgChangeRate":0.046005},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038078},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.063799},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}